Optimizing T-cell expansion: Have we reached the limit?

Cytotherapy

Volumn 11, Issue 7, 2009, Pages 813-814

  Melenhorst, J Joseph ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PEPTIDE VACCINE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL SURVIVAL; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CULTURE MEDIUM; DNA VIRUS; DONOR LYMPHOCYTE INFUSION; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MEMORY T LYMPHOCYTE; NOTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR LOCALIZATION; VIRUS IDENTIFICATION; VIRUS REACTIVATION;

EID: 70450169265     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903387163     Document Type: Note

References (14)

1. Thomas ED. Bone marrow transplantation: A review. Semin Hematol 1999;36(Suppl 7):95-103.
2. Kolb HJ, Mittermiiller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465
3. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191
4. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunode-ficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241
5. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:5 51-55
6. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
7. Zhou J, Shen X, HuangJ, Hodes RJ, Rosenberg SA, Robbins PR Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175:7046-7052
8. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
9. + T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells, J Immunother 2006;29,436-443; discussion 365-366
10. Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J, et al. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother 2007;30:506-516
11. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008; 112:1876-1885.
12. Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, et al. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy 2009;11:936-946
13. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, et al. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunc-tional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009;11:912-922
14. Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy 2009;11:923-935